• Explore /
  • Poster
  • / The Maverick trial: A phase 2 study of abivertinib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).

The Maverick trial: A phase 2 study of abivertinib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Rana R. McKay

University of California San Diego, La Jolla, CA

Rana R. McKay , Andrew J. Armstrong , Hamid Emamekhoo , Theodore Stewart Gourdin , Elisabeth I. Heath , Arif Hussain , Moshe Chaim Ornstein , Nima Sharifi , Paul Vincent Viscuse , Ying Yan , Mike A. Royal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT05361915

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS5106)

DOI

10.1200/JCO.2023.41.16_suppl.TPS5106

Abstract #

TPS5106

Poster Bd #

196a

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Genitourinary Cancers Symposium

BMX inhibition and <em>HSD3B1</em>-driven resistance in prostate cancer in the Maverick trial.

BMX inhibition and HSD3B1-driven resistance in prostate cancer in the Maverick trial.

First Author: Nima Sharifi

First Author: Yao Zhu

First Author: Mary-Ellen Taplin

First Author: Won Kim